Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
received 2nd dose of shingrix late; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of vaccine in 2023). In FEB-2025, the patient received the 2nd dose of Shingrix. In FEB-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received 2nd dose of shingrix late). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 08-APR-2025 The patient was older than 50 years old. The other health professional reported that they had a patient who received a Shingrix vaccine in 2023, and then waited another year before getting their second one. It was usually stated that, in such cases, when an individual had received the Shingrix vaccine, they got the first dose, waited two to six months for the second dose, and were then considered set. Reporter was enquiring what was recommended for people that have missed one that they had just one injection and then whether they were waiting a year or they never got their second injection also if they did start over. Patient received 2nd dose of Shingrix longer than the recommended interval which led to lengthening of vaccination schedule.